Merck: ModeX Therapeutics announces EpsteinBarr virus vaccine candidate enters phase I study in collaboration with Merck
ModeX Therapeutics Inc., an OPKO Health company, announces dosing of the first participant in the phase I study (NCT06655324) of an Epstein─Barr virus (EBV) vaccine candidate being developed in collaboration with
Read full article »
Merck is a New Jersey-based multinational biopharmaceutical company that develops and commercializes novel therapeutics and vaccines for the treatment of a range of diseases.
Read more